Re: The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
Gazzaniga
Paola
P
Silvestri
Ida
I
Gradilone
Angela
A
Aglianò
Anna Maria
AM
D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003131:Combined Modality Therapy; D015653:Cystectomy / Q000401:mortality; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D019008:Drug Resistance, Neoplasm; D015251:Epirubicin / Q000009:adverse effects*; D006801:Humans; D001749:Urinary Bladder Neoplasms / Q000401:mortality* / Q000628:therapy; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D003841:Deoxycytidine; D015251:Epirubicin; D000093542:Gemcitabine